PharmaVOICE - 
January 2007
Purchase Issue

In Every Issue
On the Calendar
January 16-17 Pharma Pricing Strategies Radisson SAS, Rome For more [...]
By
E-Media
New Electronic and Web-based Applications, Sites, and Technologies Phase Forward [...]
By
Talent Pool
Pharma POOL Lee Davies Schering-Plough Appoints Director, Global Product Communications [...]
By
Letter from the Editor
Already 2007 is shaping up to be an interesting time. [...]
By

Taren Grom, Editor

UpFront
Top 7 Healthcare Issues This year is expected to be [...]
By
For Art’s Sake
Each month, this department pays homage to memorable advertising and [...]
By
Raise Your Voice — Letters
Changes in Washington: Will it Affect the Pharmaceutical Industry? One [...]
By
PharmaOutlet
Contributed by James Rogers Merging Clinical-Trials Safety and Pharmacovigilance The [...]
By

James Rogers

What’s New
New Healthcare-related Products, Services, and Companies The breakthrough use of [...]
By
PharmaTrax
PharmaTrax Sales, Marketing, and R&D Trends from Industry Analysts Scientific [...]
By

On The Cover

Sales & Marketing Compliance: Keeping up with Global and Local Challenges
As pharmaceutical manufacturers continue to refine and adjust their compliance policies to meet a slew of regulations enacted over the past five years, they also are looking ahead and preparing for regulatory changes that could create many challenges. Six states have legislation that require pharmaceutical companies to report what they spend on physician sales, but [...]
By

Elisabeth Pena Villarroel

Features

Is EDC the next CDMS?
VIEW on Data Management Is EDC the next CDMS? The lines between EDC and CDMS continue to blur as technology catches up with practicality and the need for cleaner data faster. Glen de Vries Glen de Vries, Cofounder and Chief Technology Officer of Medidata Solutions Worldwide, discusses why EDC is not a replacement for CDMS [...]
By
Registering Safety
By Kim Ribbink As the emphasis on drug development shifts toward improving risk management, new tools have emerged to evaluate safety both pre- and postapproval. Increasingly, companies are looking at patient registries as an integral part of their safety arsenal. Drug safety has become the focal point among patients, their doctors, regulatory bodies, and pharmaceutical [...]
By

Kim Ribbink

A Commitment to Public Health — Dr. Barbara DeBuono
By Kim Ribbink Dr. Barbara DeBuono, as Senior Consultant to the WHO, was assigned to the organization’s SEARO, Southeast Asia Regional Office in New Delhi, India, to review public-health aspects of the tsunami relief and recovery operations. She worked with the WHO offices in India, Maldives, and Thailand and was on location from February through [...]
By

Kim Ribbink

Counter Measures: Switching from Rx to OTC
Switching products from Rx to OTC status can be a viable life-cycle management strategy, one that is expected to be used more frequently. By Cynthia Borda Consumers are increasingly comfortable managing their own healthcare. They want easy access to low-cost, effective, safe, and easy-to-get products, which has led to an increase in self-medication. Many of [...]
By

Cynthia Borda

FDA: An Agency in Transition
In the past year, the Food and Drug Administration has built some momentum in speeding drug development and addressing product safety. Despite the progress made in improving its internal structure, the agency in the coming year will continue to face obstacles. Robert DeLuccia MacroChem A shifting political environment will change the thrust of what’s going [...]
By

Denise Myshko

Master The New Standard: HBA Leadership Conference
HBA Leadership Conference Master The New Standard 4th Annual HBA Leadership Conference Attracts More Than 300 Attendees to Boston The 4th Annual Healthcare Businesswomen’s association’s Leadership conference, held in Boston last November, was a two-day event packed with interactive sessions, distinguished speakers, and networking opportunties. Centered around the theme Master the New Standard of Leadership, [...]
By
Managed Markets: Formularies
By Denise Myshko MCOs and PBMs are now applying their cost-management strategies to biotech and specialty drugs. Biologics and injectable medications are coming under increased scrutiny by managed care organizations (MCOs). MCOs, pharmacy benefit management companies (PBMs), and other payers are beginning to apply cost-management strategies to high-cost biologic, injectable medications, and specialty drugs. They [...]
By
Table of Contents
On the Cover Sales and marketing compliance As pharmaceutical manufacturers continue to refine and adjust their compliance policies to meet a slew of regulations over the past five years, they also are looking ahead and preparing for regulatory changes that could create many challenges. Features Registering safety As the emphasis on drug development shifts toward [...]
By
FEEDBACK